HPS Pharmacies prides itself on providing innovative and informative support to assist in the diverse range of issues health professionals face on a day-to-day basis, and to facilitate the distribution of this information for a variety of sectors within the healthcare industry.
HPS’ clinical articles are written by HPS Pharmacies’ experienced and knowledgeable staff and are peer-reviewed by specialist leaders in their field to ensure the accuracy of the information provided. The resourceful and diverse range of articles play an integral role in keeping all health professionals up-to-date with the happenings throughout the industry on a regular basis.
The benefits of low-dose aspirin in the prevention of cardiovascular events have been investigated since the 1970s following studies that finally elucidated the pharmacodynamics of aspirin, including inhibition of platelet aggregation. In 1974, a…
Read more
Hand-foot syndrome is a side-effect which can occur with treatment with some cytotoxic drugs (e.g. capecitabine, fluorouracil, liposomal doxorubicin and cytarabine) as well as multikinase inhibitors (e.g. pazopanib, sorafenib and sunitinib). Hand-foot syndrome is…
Read more
There is some uncertainty about the precautions that need to be taken while preparing and administering low dose methotrexate for rheumatoid arthritis (RA) patients either in the ward or at home. Like most drugs,…
Read more
Medication schedules Different medication schedules are handled differently when brought into a hospital setting. Types of medication schedules seen in a hospital setting can include schedule 2, 4, 4D and 8. Schedule 2 medications…
Read more
Hepatic encephalopathy (HE) is a syndrome that may occur in chronic and acute liver dysfunction. It involves a spectrum of neuropsychiatric symptoms and is associated with significant morbidity and mortality. Signs and symptoms can…
Read more
Restrictions have recently increased for the provision of proton pump inhibitors (PPIs) on the Pharmaceutical Benefits Scheme (PBS). The following changes were implemented on 1st May 2019: Standard dose PPIs changed from restricted benefit…
Read more
